EP4 agonists can induce and the EP4 antagonist GW627368x blocks EGFR-dependent degradation of the extracellular matrix that, if left unchecked, facilitates breast cancer invasion (Tönisen et al., 2017). The gene discussed is PTGER4; the disease is breast carcinoma.